Insider buying last 90 days
No open-market insider purchases were filed for SNN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Smith & Nephew's week was shaped by the collapse of its potential $34 billion merger with Johnson & Johnson's orthopaedics business, which has turned attention toward its existing wound care line, including SANTYL. Alongside this, the company's Q3 2026 trading report showed strong Sports Medicine & ENT performance offset by weaker-than-expected US knee and hip sales, prompting a cut to full-year underlying revenue growth guidance to 3% and a halving of expected trading profit growth to around 4%. This guidance revision also drew a rating downgrade from one analyst citing credibility concerns despite recent share price gains.
SNN closed at $31.05, down 0.3%, sitting between its 50-day average of $28.55 and its 200-day average of $31.02. The GekkoIndex reads 47.3, placing the stock in the Neutral zone. Shares trade 4.5% below Gekko Fair Value of $32.52, within the range the checklist treats as close to fair value.
The next earnings date falls on 1 March 2027, 111 days out and beyond a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in the current window. Seasonally, the next 20 trading days have averaged a 2.5% gain over 5 years, rising in 4 of them. Among four covering firms, all four rate the stock hold, with a consensus target of $32.32, implying 4.1% upside from current levels.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Smith & Nephew SNATS scores 2 supportive, 3 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive3 mixed0 headwinds
Averages disagree
Close $31.28 sits between the 50-day ($28.73) and 200-day ($30.96) averages, or the averages disagree.
See the chart50.2, Neutral
Reading 50.2 is in the Neutral zone.
See the GekkoIndex1.8% below
Price is within 5% of Gekko Fair Value (1.8% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 106 days
Next report Mar 1, 2027, 106 days away — outside a typical 20-trading-day hold.
See earnings+1.3% on average
From this point in the calendar, the next 20 trading days averaged +1.3% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Smith & Nephew SNATS closed at $31.28 on Nov 13, 2026, −6.5% over the past year, inside a 52-week range of $26.12 to $37.09.
Use the left and right arrow keys to read daily values.
Put SNN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Smith & Nephew SNATS develops, manufactures and sells medical devices and related services used in surgery and wound care, reaching healthcare providers in the United Kingdom, the United States and other markets. It is recognized for products supporting joint replacement, sports medicine procedures and the treatment of wounds ranging from minor injuries to chronic ulcers and burns.
The company organizes its work across three areas: orthopaedics, sports medicine and ENT, and advanced wound management. Its orthopaedics offerings include knee and hip implants along with trauma and extremities devices for stabilizing fractures and correcting deformities. The sports medicine and ENT segment supplies instruments and implants for minimally invasive joint repair, along with visualization and tissue resection tools used during arthroscopic surgery, plus ear, nose and throat products. The wound management segment covers dressings and devices for acute and chronic wounds, along with bioactive and regenerative products such as skin and bone graft substitutes, all sold to hospitals and other healthcare providers.
Smith & Nephew SNATS traces its founding to 1856 and is headquartered in Watford, in the United Kingdom. Its shares trade under the ticker SNN.
Smith & Nephew SNATS’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 50.2, in the Neutral zone, up 6 points over five sessions.
Up 6 points over five sessions, from the Distribution zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 53 | +0.9% | +0.9% | ||
| Accumulation | 232 | 0.0% | +0.8% | ||
| Neutral (current zone) | 335 | +0.3% | +0.8% | ||
| Distribution | 35 | +0.2% | +2.7% | ||
| Selling | 0 | Not available | |||
Average SNN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Smith & Nephew SNATS trades 1.8% below Gekko Fair Value of $31.84, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Smith & Nephew SNATS shares are worth, recalculated every trading day.
$31.84
Gekko Fair Value, Nov 14, 2026
1.8% below fair value · About fair value
At the end of Aug 2026 the price was 10.6% below the estimate.
No open-market insider purchases were filed for Smith & Nephew SNATS, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for SNN in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in SNN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Smith & Nephew SNATS has been buying back its own shares.
From company filings.
0of the funds Gekko tracks hold SNN.
Smith & Nephew SNATS reports on Mar 1, 2027 (106 days away).
Mar 1, 2027
106 days away
Analysts’ average 12-month price target for Smith & Nephew SNATS is $33.19, +6.1% from the last close, from 3 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 3 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 9 | BTIG | — | — |
| Nov 5 | Canaccord Genuity | $33 | +5.5% |
| Nov 4 | Bank of America Securities | — | — |
| Nov 4 | BTIG | — | — |
| Oct 6 | Bank of America Securities | $14.58 | −53.4% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Smith & Nephew SNATS averaged +1.3% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.1% | 3 of 5 |
| Next 10 trading days | −0.3% | 4 of 5 |
| Next 15 trading days | +1.1% | 4 of 5 |
| Next 20 trading days | +1.3% | 3 of 5 |
| Next 30 trading days | +2.1% | 4 of 5 |
For scale, SNN’s typical 20-trading-day move in either direction is about 4.9%.
Smith & Nephew SNATS’s market cap is $13.09B, with a P/E ratio of 21.4 and revenue of $6.30B over the last twelve months.
Coverage of Smith & Nephew SNATS this week reads neutral: 1 positive, 2 neutral and 1 negative headlines.
Smith & Nephew SNATS’s market cap is $13.09B at the Nov 13, 2026 close of $31.28, with 418.5M shares outstanding. The shares trade on a P/E ratio of 21.4.
The consensus analyst 12-month price target for Smith & Nephew SNATS is $33.19, +6.1% from the last close. Of the 3 firms that rated the stock in the last 90 days, 0 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Smith & Nephew SNATS is about fair value: the Nov 13, 2026 close of $31.28 is 1.8% below Gekko Fair Value of $31.84. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Smith & Nephew SNATS is expected to report on Mar 1, 2027 (106 days away). Analysts expect earnings of $1.20 per share on revenue of $3.31B.
Smith & Nephew SNATS’s 52-week high is $37.09 and its 52-week low is $26.12; it closed at $31.28 on Nov 13, 2026, −6.5% over the past year. Over the last five years the shares peaked at $38.79 on Sep 9, 2025.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (earnings risk and seasonality), 3 as mixed (trend, gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.